Top MarketRank™ StocksTop MarketRank™NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis $120.17 -1.04 (-0.86%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$119.85▼$122.7550-Day Range$120.17▼$153.1552-Week Range$103.63▼$157.98Volume868,975 shsAverage Volume854,996 shsMarket Capitalization$12.09 billionP/E Ratio33.10Dividend YieldN/APrice Target$163.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Neurocrine Biosciences alerts: Email Address Neurocrine Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside35.6% Upside$163.00 Price TargetShort InterestHealthy2.28% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.51Based on 5 Articles This WeekInsider TradingSelling Shares$10.68 M Sold Last QuarterProj. Earnings Growth68.74%From $4.19 to $7.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.95 out of 5 starsMedical Sector12th out of 910 stocksBiological Products, Except Diagnostic Industry1st out of 155 stocks 4.4 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 18 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.28% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently decreased by 14.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 1.4 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Neurocrine Biosciences this week, compared to 10 articles on an average week.Search InterestOnly 4 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,676,096.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 68.74% in the coming year, from $4.19 to $7.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 33.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 33.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.06.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 4.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurocrine Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Neurocrine Biosciences Stock (NASDAQ:NBIX)Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Read More NBIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBIX Stock News HeadlinesAugust 17, 2024 | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director William H. Rastetter Sells 14,250 SharesAugust 16, 2024 | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $1,072,164.30 in StockSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 9, 2024 | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $40,322.10 in StockSeptember 6 at 1:14 PM | markets.businessinsider.comNeurocrine’s Robust Drug Pipeline and Strategic Launch Preparations Bolster Buy RatingAugust 31, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) PT Lowered to $136.00August 31, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $155.00August 30, 2024 | seekingalpha.comNeurocrine upped to overweight by Piper, sees '568 as still viableSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for Neurocrine on Market Potential and Superior Safety ProfileAugust 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for Neurocrine Biosciences Amidst Therapeutic Development and Valuation ProspectsAugust 30, 2024 | msn.comPiper Sandler Upgrades Neurocrine Biosciences (NBIX)August 30, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Receives Buy Rating from HC WainwrightAugust 30, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Given New $128.00 Price Target at BMO Capital MarketsAugust 30, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Upgraded by Piper Sandler to OverweightAugust 30, 2024 | fool.comWhy Neurocrine Biosciences Stock Was Tumbling This WeekAugust 30, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Shares Gap Down to $152.55August 29, 2024 | markets.businessinsider.comBuy Rating on Neurocrine: Analyzing Phase 2 Data and Long-Term Commercial ProspectsSee More Headlines Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,400Year FoundedN/APrice Target and Rating Average Stock Price Target$163.00 High Stock Price Target$219.00 Low Stock Price Target$128.00 Potential Upside/Downside+35.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)$3.63 Trailing P/E Ratio33.10 Forward P/E Ratio28.68 P/E GrowthN/ANet Income$249.70 million Net Margins16.00% Pretax Margin21.08% Return on Equity14.86% Return on Assets10.54% Debt Debt-to-Equity RatioN/A Current Ratio4.19 Quick Ratio4.08 Sales & Book Value Annual Sales$2.12 billion Price / Sales5.71 Cash Flow$2.44 per share Price / Cash Flow49.27 Book Value$24.85 per share Price / Book4.84Miscellaneous Outstanding Shares100,637,000Free Float96,310,000Market Cap$12.09 billion OptionableOptionable Beta0.37 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Kevin C. Gorman Ph.D. (Age 66)CEO & Director Comp: $2.05MMr. Matthew C. Abernethy (Age 44)Chief Financial Officer Comp: $1.06MDr. Jude Onyia Ph.D. (Age 60)Chief Scientific Officer Comp: $1.22MMr. Kyle W. Gano Ph.D. (Age 51)Chief Business Development & Strategy Officer Comp: $990.12kDr. Eiry Wyn Roberts M.D. (Age 60)Chief Medical Officer Comp: $1.12MJane SorensenHead of Investor RelationsMr. Darin M. Lippoldt Esq. (Age 58)Chief Legal Officer & Corporate Secretary Comp: $921.01kMs. Julie S. Cooke (Age 58)Chief Human Resources Officer Mr. Eric S. Benevich (Age 59)Chief Commercial Officer Comp: $805kMr. David Warren Boyer (Age 44)Chief Corporate Affairs Officer More ExecutivesKey CompetitorsBio-TechneNASDAQ:TECHAcceleron PharmaNASDAQ:XLRNQiagenNYSE:QGENMomenta PharmaceuticalsNASDAQ:MNTACRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 3,751 shares on 9/5/2024Ownership: 0.004%Aurora Investment CounselSold 118 shares on 8/22/2024Ownership: 0.010%Cetera Investment AdvisersBought 519 shares on 8/22/2024Ownership: 0.007%Truist Financial CorpSold 5,802 shares on 8/21/2024Ownership: 0.031%Driehaus Capital Management LLCSold 294 shares on 8/16/2024Ownership: 0.071%View All Insider TransactionsView All Institutional Transactions NBIX Stock Analysis - Frequently Asked Questions How have NBIX shares performed this year? Neurocrine Biosciences' stock was trading at $131.76 on January 1st, 2024. Since then, NBIX shares have decreased by 8.8% and is now trading at $120.17. View the best growth stocks for 2024 here. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings results on Thursday, August, 1st. The company reported $0.63 EPS for the quarter, missing analysts' consensus estimates of $1.15 by $0.52. Neurocrine Biosciences's revenue was up 30.4% on a year-over-year basis. What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' top institutional investors include Renaissance Technologies LLC (2.45%), AQR Capital Management LLC (1.22%), DSM Capital Partners LLC (0.99%) and Armistice Capital LLC (0.97%). Insiders that own company stock include Neurocrine Biosciences Inc, Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Eric Benevich, William H Rastetter, Darin Lippoldt, Matt Abernethy, Richard F Pops, Stephen A Sherwin, Eiry Roberts, Malcolm Lloyd-Smith, Julie Cooke, Jude Onyia, David W Boyer, Ingrid Delaet, Shalini Sharp, Leslie V Norwalk, George J Morrow and Dimitri E Grigoriadis. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV) and Walt Disney (DIS). This page (NASDAQ:NBIX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
